Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors

Summary: Terremoto Biosciences just scored $108 million to test new medicines for cancer and a rare bleeding disorder called HHT. Most drugs of this type attach to a rare building block in the body called cysteine. Terremoto is doing something completely new by attaching their drugs to a much more common building block called lysine.

Former CEO Peter Thompson called this complicated chemistry a game of "dynamic Tetris." By targeting a specific protein called AKT1, the company hopes to stop these complex diseases without causing bad side effects like rashes or blood sugar issues, which happen when drugs accidentally hit a similar protein called AKT2. Now, with former Pfizer cancer expert Charles Baum taking over as the new CEO, the company is using its massive new funding to take these drugs into human testing.

For more details, see rssapp-fiercebiotech-com at fiercebiotech.com/biotech/terremoto-takes-108m-series-c-fuel-clinical-trials-akt1-inhibitors (opens in new tab)